BRAF and melanoma: In another study, OncomineTM Pan-Cancer Cell-Free Assay, a 52-gene panel, was performed on a tumor and was compared to its application on ctDNA plasma samples from 22 advanced melanoma patients before first-line treatment (BRAF/MEKi or ICI) [126].